Source: International Congress 2014 – Clinical management of lung diseases: from bronchi to pleura
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Weiser, B. Guth, G. Rast, M. Markert, H. Fuchs, A. Liesener (Ingelheim, Biberach, Germany). The antitussive pentoxyverine (POV) has a low proarrhythmic risk based on an in vitro and in vivo integrated risk assessment. Eur Respir J 2014; 44: Suppl. 58, 581

Member's Comments

No comment yet.

Related content which might interest you: New method of evaluation of beta-receptors' affinity and expression Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases Year: 2014 The antitussive pentoxyverine (POV) does not affect the electrocardiogram (ECG), and in particular not the corrected QT (QTc) interval: Results from a phase I clinical trial Source: International Congress 2014 – Clinical management of lung diseases: from bronchi to pleura Year: 2014 Establishment and evaluation of a new measurement of cough reflex sensitivity: Cough provocation by agonist of TRPA1 (cinnamaldehyde) Source: International Congress 2014 – Clinical management of lung diseases: from bronchi to pleura Year: 2014 Bronchoprotective activity and safety assessment of two novel dual-acting MABA compounds (LAS190792 and LAS191351) in dogs Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 REG endpoint validation: Do database asthma control measures predict future risk? Source: International Congress 2014 – Management of asthma and other respiratory diseases in primary care Year: 2014 A new clinically relevant method of calculating adherence Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 The effects of clinically relevant reference agents in a mouse model of severe asthma Source: International Congress 2015 – Advances in the future treatment of severe asthma Year: 2015 Identifying patients at risk for future exacerbations of asthma: Development of a prediction model Source: International Congress 2015 – Non-inflammatory monitoring of airway diseases Year: 2015 Paradoxical response to bronchodilators: Radiologic correlates and clinical implications Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases Year: 2014 Metrics of salbutamol use as predictors of future adverse outcomes in asthma Source: Annual Congress 2013 –Quality of diagnosis and assessment in primary care Year: 2013 Can blood investigations be utilised to predict treatment response to omalizumab? Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 Pharmacological profile of a novel, potent and oral TRPA1 antagonist. Characterization in a preclinical model of induced cough Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 The in vitro profile of ADC3680, a potent and selective CRTh2 antagonist for the treatment of inadequately controlled asthma Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 Exercise-induced bronchoconstriction in a school-age cohort: Prevalence, risk factors and utility of the Cooper test for its routine detection Source: International Congress 2014 – Alterations of exercise and lung function in different diseases Year: 2014 Patient reported outcomes for the measurement of physical activity in COPD patients. The PROactive tools Source: Annual Congress 2013 –Factors associated with outcomes in COPD Year: 2013 Validation of FEV1 spirometric endpoints as a measure of the anti-inflammatory and bronchodilatory effects of fluticasone/formoterol combination therapy Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Systemic exposure and lung bioavailability across two different dose strengths of CHF5993 a novel Triple pMDI Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 Usefulness of standard end points of capsaicin cough challenge in health and disease Source: International Congress 2014 – Clinical management of lung diseases: from bronchi to pleura Year: 2014 Use of β-blockers and the risk of asthma exacerbations Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016 Clinical, functional and laboratory assessment of treatment efficacy in COPD patients Source: International Congress 2014 – Predictors Year: 2014